Traws Pharma, Inc.
TRAW
$2.16
-$0.32-12.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 2.73M | 57.00K | 56.00K | 57.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 2.73M | 57.00K | 56.00K | 57.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 2.73M | 57.00K | 56.00K | 57.00K |
| SG&A Expenses | 1.74M | 1.69M | 2.75M | 3.48M | 3.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.06M | 3.98M | 5.26M | 5.33M | 8.59M |
| Operating Income | -4.06M | -1.25M | -5.20M | -5.28M | -8.54M |
| Income Before Tax | -3.96M | -915.00K | 21.49M | -29.92M | -8.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.96M | -915.00K | 21.49M | -29.92M | -8.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.96M | -915.00K | 21.49M | -29.92M | -8.48M |
| EBIT | -4.06M | -1.25M | -5.20M | -5.28M | -8.54M |
| EBITDA | -4.04M | -1.25M | -5.20M | -5.28M | -8.53M |
| EPS Basic | -0.34 | -0.11 | 2.17 | 26.60 | -1.49 |
| Normalized Basic EPS | -0.28 | -0.10 | 1.93 | -6.07 | -5.51 |
| EPS Diluted | -0.34 | -0.11 | 2.09 | 26.60 | -1.49 |
| Normalized Diluted EPS | -0.28 | -0.10 | 1.86 | -6.07 | -5.51 |
| Average Basic Shares Outstanding | 8.82M | 5.82M | 6.97M | 3.08M | 961.50K |
| Average Diluted Shares Outstanding | 8.82M | 5.82M | 7.22M | 3.08M | 961.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |